Sales for 1996 at Astra of Sweden amounted to just under 39 billionSwedish kroner ($5.26 billion), an increase of 9%. The company noted that calculated at constant exchange rates, sales growth for the year was 17%. Net price changes did not impact sales growth during the year, the firm said.
Pretax earnings of 13.22 billion kroner grew 10% in 1996, and earnings per share, at 15.33 kroner, were up 8%. At constant exchange rates pretax profits were ahead 17%. The firm's operating earnings were 12.22 billion kroner, an increase of 10% on the previous year. Net profits were just over 1 billion kroner, compared to 950 million kroner a year earlier. Financial exchange rate differences totalled 32 million kroner.
Astra's pretax profits and EPS came in ahead of Goldman Sachs analysts Mark Tracey and John Murphy's expectations, which were pretax profits of 12.65 billion kroner and EPS of 14.70 kroner.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze